The A459 tumour weights of the group treated with αEGFR-mAB-P/KRAS-siRNA/P nanostructures were significantly diminished in comparison to the control-siRNA loaded αEGFR-mAB-P/P nanostructure group (Fig. 6F). This evidence concerns the gene KRAS and neoplasm.